RxDoctor Payments Data

Steven Cessna

Psychiatric/Mental Health · Hammond, LANPI 1346750916

Payments from drug & device makers

$1,799in general payments, 2019–2025

Across 112 payments — averaging $16.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$359
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$292
  • Johnson & Johnson$173
  • Otsuka America Pharmaceutical, Inc.$168
  • Neurocrine Biosciences, Inc.$152
  • Lundbeck LLC$121
  • plus $533 from 12 others

What the payments were for

  • Food & beverage$1,77098%
  • Education$282%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,799 in reported general payments places this provider in the 55th percentile of 615 psychiatric/mental health providers in Louisiana.

See all psychiatric/mental health providers in Louisiana

Medicare billing

Part B allowed, 2024
$2,200
Medicare patients
24
Services billed
39

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate26$68,778
LatudaLurasidone Hcl18$37,675
ZubsolvBuprenorphine Hcl/Naloxone Hcl22$18,228
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl75$12,937
Oxcarbazepine75$3,122
Lurasidone Hcl80$2,885
Quetiapine Fumarate126$1,285
Venlafaxine Hcl ErVenlafaxine Hcl51$1,054
Aripiprazole70$1,045
Trazodone Hcl108$806
Duloxetine Hcl38$717
Bupropion XlBupropion Hcl66$704
Mirtazapine67$649
Haloperidol Decanoate12$602
Prazosin Hcl50$591

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$173$68,77826 claims
Sunovion Pharmaceuticals Inc.Latuda$48$37,67518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 615 psychiatric/mental health providers in Louisiana.

Other psychiatric/mental health in Hammond

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →